KZIA
Kazia Therapeutics Ltd
9.30$
-2.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Kazia Therapeutics Ltd (KZIA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -13 million AUD. Tick rows to compare them in a chart.
All figures in millions of AUD.
Tick rows to compare them in a chart (up to 4)
| Line item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21 | -19 | -34 | -6.7 | -5.8 | -10 | -13 | -14 | -15 | -20 | -21 | -17 | -8.7 | -7.3 | -8.8 | -5.7 | -5.8 | -12 | -11 | -8.7 | -6.7 | -8.8 | -9.1 | -23 | -15 | -9.6 | -13 | |
| 1.3 | – | – | 1.9 | 1.9 | 1.7 | 1.6 | 1.4 | 1.0 | 0.4 | 0.3 | 0.2 | 0.1 | 0.0 | 0.3 | 0.6 | 0.6 | 0.6 | 1.4 | 1.5 | 1.1 | 1.1 | 1.3 | 1.9 | 1.9 | 1.9 | 0.9 | |
| – | – | – | – | – | – | – | – | – | – | 1.2 | 0.7 | 0.7 | 0.6 | 0.4 | – | – | 0.4 | 0.5 | 0.2 | 0.2 | 0.3 | 0.6 | 1.7 | 1.2 | 0.5 | 0.7 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.7 | -0.1 | 0.2 | 1.8 | -5.7 | 2.1 | 0.9 | 3.6 | 0.0 | -0.9 | – | – | |
| -5.8 | 2.9 | 4.5 | 5.7 | 2.9 | -0.1 | -2.1 | 1.2 | 5.0 | 4.4 | 1.7 | -2.3 | 0.3 | 1.4 | -3.3 | 0.5 | 1.1 | -0.7 | -4.0 | 1.5 | 0.4 | 1.7 | -5.6 | 0.9 | 4.3 | 10 | -3.0 | |
| 4.9 | 2.7 | 1.9 | 1.9 | 0.8 | 0.7 | 0.8 | 0.3 | 0.3 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -4.9 | -2.6 | – | -0.1 | -0.7 | – | -0.8 | -0.3 | 0.0 | 3.7 | -0.1 | 0.0 | 0.3 | 0.0 | 0.2 | 0.0 | -0.1 | -0.5 | -7.1 | 0.2 | 2.4 | -2.4 | -2.4 | -2.4 | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | |
| – | – | – | – | – | -3.3 | -3.3 | – | – | – | – | – | – | – | – | 50 | 50 | 0.9 | 0.0 | 0.0 | 3.8 | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 5.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | 0.0 | 0.0 | 0.4 | 0.0 | |
| 41 | 20 | 40 | 16 | 0.1 | 37 | 6.1 | 0.0 | 25 | 17 | 12 | – | 0.8 | 1.7 | 3.0 | 5.5 | 47 | 0.8 | 0.0 | 3.8 | 3.8 | 12 | 28 | 3.7 | 13 | 6.0 | 16 | |
| 15 | -1.2 | 4.5 | 8.8 | -8.9 | 27 | -11 | -14 | 8.0 | -4.1 | -2.0 | -18 | -8.4 | 2.3 | -5.6 | -0.2 | 42 | -11 | -19 | -8.5 | -0.5 | 3.3 | 19 | -20 | -2.1 | -3.6 | 2.7 | |
| -26 | -21 | -36 | -6.7 | -6.6 | -11 | -14 | -15 | -15 | -20 | -21 | -17 | -8.8 | -7.4 | -8.8 | -5.7 | -5.9 | -13 | -11 | -8.7 | -6.7 | -8.8 | -9.1 | -23 | -15 | -9.6 | -13 |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.